Technical Analysis for AMRN - Amarin Corporation plc
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| See historical AMRN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 2.30% | |
| Stochastic Buy Signal | Bullish | 2.30% | |
| Narrow Range Bar | Range Contraction | 2.30% | |
| NR7 | Range Contraction | 2.30% | |
| Up 3 Days in a Row | Strength | 2.30% | |
| Oversold Stochastic | Weakness | 2.30% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/01/2019
- Sector: Healthcare
- Industry: Biotechnology
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids. The company lead product comprises Vascepa, a prescription-only omega-3 fatty acid comprising icosapent ethyl as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It also engages in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is headquartered in Dublin, Ireland.
Biopharmaceutical Organic Compounds Nutrition Cardiovascular Diseases Cholesterol Low Density Lipoprotein Lipids Hypertriglyceridemia Saturated Fat
Biopharmaceutical Organic Compounds Nutrition Cardiovascular Diseases Cholesterol Low Density Lipoprotein Lipids Hypertriglyceridemia Saturated Fat
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more AMRN news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 23.335 |
| 52 Week Low | 2.35 |
| Average Volume | 6,470,665 |
| 200-Day Moving Average | 15.2697 |
| 50-Day Moving Average | 18.7732 |
| 20-Day Moving Average | 17.9035 |
| 10-Day Moving Average | 17.288 |
| Average True Range | 0.8389 |
| ADX | 17.39 |
| +DI | 21.3929 |
| -DI | 21.2115 |
| Chandelier Exit (Long, 3 ATRs ) | 16.8733 |
| Chandelier Exit (Short, 3 ATRs ) | 18.7167 |
| Upper Bollinger Band | 19.5242 |
| Lower Bollinger Band | 16.2828 |
| Percent B (%b) | 0.46 |
| BandWidth | 18.10484 |
| MACD Line | -0.459 |
| MACD Signal Line | -0.4522 |
| MACD Histogram | -0.0068 |
| Fundamentals | Value |
|---|---|
| Market Cap | 4.82 Billion |
| Num Shares | 271 Million |
| EPS | -0.31 |
| Price-to-Earnings (P/E) Ratio | -57.39 |
| Price-to-Sales | 5.87 |
| Price-to-Book | 0.00 |
| PEG Ratio | -1.74 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 19.08 | ||||
| Resistance 3 (R3) | 19.01 | 18.51 | 18.87 | ||
| Resistance 2 (R2) | 18.51 | 18.18 | 18.55 | 18.79 | |
| Resistance 1 (R1) | 18.15 | 17.98 | 18.33 | 18.22 | 18.72 |
| Pivot Point | 17.65 | 17.65 | 17.74 | 17.69 | 17.65 |
| Support 1 (S1) | 17.29 | 17.32 | 17.47 | 17.36 | 16.86 |
| Support 2 (S2) | 16.79 | 17.12 | 16.83 | 16.79 | |
| Support 3 (S3) | 16.43 | 16.79 | 16.72 | ||
| Support 4 (S4) | 16.50 |
